Search results for: 'use interface market'

Clinical genomics regained significance during the pandemic with the development of the mRNA COVID-19 vaccine, and several non-invasive at-home test kits; an unprecedented feat in recent times. Genomics will take center stage, as large genome sequencing and research will continuously create data for new therapeutics. Artificial Intelligence (AI) an...

23 Aug 2022  |  North America  |  Frost Radar

Frost Radar™: US Liquid Biopsy, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comp...

Today, the journey of starting a family does not look the way it did fifty years ago, and people are turning to fertility services for help. 1 in 8 couples in the United States experience pregnancy-related difficulties that fertility treatments can address. Key market drivers include the increasing rate of obesity causing deterred ovulation in wom...

14 Jan 2019  |  North America  |  Market Research

Growth Opportunities in the Global qPCR and dPCR Market, Forecast to 2023

Novel Applications in Oncology and Applied Sciences, Growing Research and Diagnostic Use in Developing Regions, and Automated Modular Workflows to Drive Growth

Infographics

×

Key Issues Addressed

Overview: PCR continues to be the gold standard for nucleic acid amplification by combining accuracy and efficacy that users across areas such as research, pharma & biotech, diagnostics as well as applied sciences depend upon. Such widespread usage continues to drive the industry, even protecting it to some extent from overall economic/market fluct...

The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus o...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

Management of infectious diseases remains a critical challenge for public health professionals who face increasing demand to control the spread of existing and novel diseases. To provide appropriate healthcare assistance, it is imperative to diagnose the exact form of infection from an array of complicated symptoms expressed by the host. As the out...

This study analyzes the in vitro fertility (IVF) services market across the globe. With infertility rates increasing across the world, assisted reproductive technologies (ART), including IVF, are gaining prominence. With technology advancements, the IVF process has undergone several modifications, with mainstream service providers such as fertility...

The Transformational Health team at Frost & Sullivan provides critical insights into the US clinical chemistry and immunoassay industry, highlighting the recent activities, key growth opportunities, and trends that are shaping the industry. The already dynamic in vitro diagnostics landscape in the United States was affected even more by the recen...